Enteric fever, primarily caused by Salmonella Typhi and Paratyphi, remains a significant global health concern, especially in developing countries. The disease's management is increasingly complex due to emerging antibiotic resistance. This article outlines comprehensive strategies for effective enteric fever management.
Early diagnosis is crucial for effective enteric fever management. The Widal test, though widely used, has limited sensitivity and specificity. More accurate diagnostic methods, such as blood culture and molecular techniques, should be employed whenever possible. Rapid diagnostic tests, like Typhidot and Tubex, can also be useful, particularly in resource-limited settings.
Antibiotic therapy is the mainstay of enteric fever treatment. However, increasing antibiotic resistance, especially to first-line drugs like chloramphenicol, ampicillin, and trimethoprim-sulfamethoxazole, necessitates a judicious approach to antibiotic use. Current guidelines recommend third-generation cephalosporins or fluoroquinolones as first-line therapy in most settings. However, local susceptibility patterns should guide antibiotic choice.
Vaccination is a key preventive measure against enteric fever. Currently, two vaccines (Ty21a and Vi polysaccharide) are available and recommended for individuals in high-risk areas and travelers to such regions. However, their use is limited by moderate efficacy and short duration of protection. Continued efforts to develop more effective vaccines are essential.
Public health interventions, such as provision of safe water, adequate sanitation, and food safety measures, play a crucial role in controlling enteric fever. These interventions, combined with vaccination and antibiotic stewardship programs, can significantly reduce the disease burden.
Effective management of enteric fever requires a comprehensive approach, encompassing early diagnosis, appropriate antibiotic therapy, vaccination, and public health measures. Ongoing research into improved diagnostic methods, new antibiotics, and more effective vaccines will further enhance our ability to control this significant global health threat.
1.
Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable Safety
2.
As EGFR internalization is decreased, BUB1 controls EGFR signaling.
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
Low Income, Education Tied to Depression in Older Adults
5.
In Higher-Risk MDS, CMML, All-Oral Therapy Has Promise.
1.
Bridging Disciplines: Medical Oncology vs Surgical Oncology in the Era of Multidisciplinary Cancer Care
2.
Next-Gen CAR Cell Therapies in Oncology: Frontiers in Solid Tumors & Hematologic Malignancies
3.
Next-Generation Sequencing in Oncology: Unlocking the Future of Precision Medicine
4.
Unlocking the Key to Treating Lymphoma: New Innovations in Cancer Research
5.
Personalizing Cancer Care: Microbiome Advances, Challenges, and Future Directions
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
2.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
4.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
5.
Navigating the Complexities of Ph Negative ALL - Part XV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation